Project 1.4 Patient Safety in the Ambulatory Care Setting Metric
Specification Manual v2.0
PRIME Project 1.4 Patient Safety in the Ambulatory Care Setting
Metric Specification Manual v2.1
Document Control Log
Version
Date
Details
V1.0
2/29/16
Metric specifications not arranged by Project
Metric specifications in native format without editing
V2.0
3/7/16
Metrics arranged by Project
Metric specifications edited for PRIME
V2.1
4/29/16
Added PRIME Eligible Population for DMPHs
Added sentence requiring inclusion of individuals who meet
either Population #1or
#2 criteria.
Modified continuous enrollment language for PRIME Eligible
Population #2 to be
12 months during the Measurement Period
Replaced “Appendix 2” with “Table 5” in GPP footnote
Deleted reporting of three rates in 1.4.2 NQF 2371
Revised specification and Summary Table for 1.4.1 Abnormal
Results Follow-up
V2.2
5/31/16
Approved by DHCS
Added exclusion of inpatient encounters in PRIME Eligible
Population #1
Added PRIME Eligible Population Tenure and Exclusion
criteria
Revised summary table for 1.4.1 to align with measure
numerator/denominator
Removed the word “abnormal” in 1.4.1 denominator to align with
the INR &
mammogram denominators in the same metric.
Added Exclusions and definition of “Ambulatory Care
Tests/Ambulatory Setting” in
1.4.1 Abnormal Results Follow-up
Added “INR Test” and “Interval” language from original specs to
Numerator Details
under 1.4.3 NQF 0555
V2.3
6/30/16
Approved by DHCS
Added time criteria to PRIME Eligible Population incarceration
exclusion
Added specifications for look back period for 1.4.1 BIRADS 1-3
follow-up.
Defined the Index and follow-up mammogram measurement periods in
1.4.1 for each DY
for BIRADS 1-3 follow-up
Removed link to Metric Question Form
Measurement Periods
Demonstration Year
Mid-Year Report Measurement Period
Final Year-End Report Measurement Period
DY 11
Not applicable
Jul 1, 2015 – Jun 30, 2016
DY12
Jan 1, 2016 – Dec 31, 2016
Jul 1, 2016 – Jun 30, 2017
DY13
Jan 1, 2017 – Dec 31, 2017
Jul 1, 2017 – Jun 30, 2018
DY14
Jan 1, 2018 – Dec 31, 2018
Jul 1, 2018 – Jun 30, 2019
DY15
Jan 1, 2019 – Dec 31, 2019
Jul 1, 2019 – Jun 30, 2020
Note: Specifications for PRIME measures that are CMS Core
measures refer to CMS value sets[footnoteRef:1] [1: A CMS value set
is the complete set of codes used to identify a service or
condition included in a measure. The value set references are
underlined in the specifications (e.g. BMI Percentile Value Set).
The Value Set Directory is available at:
http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Quality-of-Care/Downloads/2015-Adult-Value-Set-Directory.zip,
Accessed on 2/26/2016. For a Value Set Directory User Manual, refer
to Appendix A in the 2015 Core Set of Adult Health Care Quality
Measures for Medicaid.]
PRIME Eligible Population for Designated Public Hospitals (DPHs)
only:
The PRIME Eligible Population includes the combination of both
Population #1 and Population #2. An individual does not have to
meet criteria of both Population #1 and Population #2. Any
individual who meets either PRIME Eligible Population #1 criteria
or PRIME Eligible Population #2 criteria must be included in the
PRIME Eligible Population.
Population #1:
Individuals of all ages with at least 2 encounters with the
PRIME Entity Primary Care team during the measurement period.
· A Primary Care team encounter is counted if occurred with a
member of the Primary Care Team from Family Medicine, Internal
Medicine, or Pediatrics. The PRIME Entity may choose to include
populations who are seen for primary care in a specialty clinic
(e.g. HIV)
· Encounters include either a face-to-face visit with a primary
care provider OR any encounter included in the list of eligible
non-traditional service types described in the Global Payment
Program[footnoteRef:2] (for PRIME, encounters not limited to
uninsured individuals.) [2: Non-traditional service encounters as
listed in California’s MediCal 2020 Special Terms and Conditions
Attachment FF: Global Payment Program Valuation Protocol, Table 5:
Categories of Service and Point Values, Non-Traditional]
· Only encounters with the Primary Care team in the ambulatory
setting will be counted toward the above 2 encounter requirement.
Encounters with primary care team members in the inpatient setting
do not count toward the two primary care encounter requirement.
[This does not impact the expansion of the PRIME Eligible
Population to include inpatient or acute care utilization as
specified by the Project Target Population criteria e.g. in Domain
3]
Population #2
Individuals of all ages who are in Medi-Cal Managed Care with 12
months of continuous assignment to the PRIME Entity during the
Measurement Period.
· No more than one gap in enrollment or assignment with the
PRIME Entity of up to 45 days during the Measurement Period.
· Individual must be enrolled in the primary plan and assigned
to the PRIME Entity on the final day of the Measurement Period.
PRIME Eligible Population for District Municipal Hospitals
(DMPHs) only:
The PRIME Eligible Population is all individuals with at least
two encounters by the participating PRIME entity among Medi-Cal
Beneficiaries.
Tenure Criteria for DPH/DMPH PRIME Eligible Population
Encountered Lives
1. The first of the two required primary care encounters (DPH)
or Medi-Cal encounters (DMPH) must occur during the first 6 months
of the measurement period
2. The second required (primary care) encounter may occur at any
point during the measurement period.
3. The two (primary care) encounters during the measurement
period fulfilling the PRIME Eligible Population eligibility
criteria cannot occur on the same day.
Exclusion Criteria for DPH/DMPH PRIME Eligible Population
Exclusion for patients no longer the responsibility of the PRIME
Entity at the end of the measurement period:
1. Any patient meeting the PRIME Eligible Population Encountered
Lives criteria in a given measurement period who then experiences
any of the following scenarios, will be removed from the PRIME
Eligible Population for that measurement period, when the PRIME
entity has documentation that before the end of the measurement
period:
a. The patient has died.
b. The patient has changed their care to a PCP in a health
system that is not the PRIME Entity.
c. The patient has had a total time of incarceration during the
measurement period that exceeded 45 days, regardless of the number
of times the individual was incarcerated during the measurement
period.
PRIME Project 1.4 Target Population is the PRIME Eligible
Population as defined above.
Summary Table
This table does not contain all the criteria for the numerator
and denominator. Adhere to the metric specification.
1.4.2 - NQF 2371: Annual Monitoring for Patients on Persistent
Medications
Specification Source: : 2015 Core Set of Adult Health Care
Quality Measures for Medicaid v. April 2015
Numerator: This measure is reported as a total rate. For annual
monitoring for patients on ACE inhibitors or ARBs: the number of
patients with at least one serum potassium and serum creatinine
therapeutic monitoring test in the measurement year. For annual
monitoring for patients on digoxin: the number of patients with at
least one serum potassium, one serum creatinine, and a serum
digoxin therapeutic monitoring test in the measurement year. For
annual monitoring for patients on diuretics: the number of patients
with at least one serum potassium and serum creatinine therapeutic
monitoring test in the measurement year. For the total rate: sum of
the 3 numerators.
Denominator: Patients age 18 and older as of the end of the
measurement year who are on selected persistent medications (ACE
Inhibitors/ARB, Digoxin or Diuretics.)
1.4.1 - Abnormal results follow-up: % of abnormal results with
appropriate and timely documentation and follow-up
Specification Source: PRIME Innovative Measure Steward
Numerator: Number of denominator serum Potassium, INR tests or
mammograms that have had appropriate follow-up
Denominator: The number of serum potassium, INR tests or
mammograms completed in the ambulatory setting during the
measurement year in PRIME Eligible Population patients age 18 and
older, as of the end of the measurement period, who are on selected
persistent medications (ACE Inhibitors/ARB, Diuretics, or
Warfarin), or who was assessed for breast cancer with a
mammogram.
1.4.3 - NQF 0555: INR Monitoring for Individuals on Warfarin
Specification Source:
https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Downloads/NQF-0555.zip
Numerator: The number of individuals in the denominator who have
at least one INR monitoring test during each 56-day interval with
active warfarin therapy.
Denominator:
Individuals at least 18 years of age as of the beginning of the
measurement period with warfarin therapy for at least 56 days
during the measurement period.
1.4.2 - NQF 2371 Annual Monitoring for Patients on Persistent
Medications
MEASURE MPM-AD: ANNUAL MONITORING FOR PATIENTS ON PERSISTENT
MEDICATIONS
National Committee for Quality Assurance
A. DESCRIPTION
Percentage of individuals in the Project 1.4 Target Population
age 18 and older who received at least 180 treatment days of
ambulatory medication therapy for a select therapeutic agent during
the measurement year and at least one therapeutic monitoring event
for the therapeutic agent in the measurement year. Report as a
total rate.
•Annual monitoring for individuals on angiotensin converting
enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB)
•Annual monitoring for individuals on digoxin
•Annual monitoring for individuals on diuretics
•Total rate (the sum of the three numerators divided by the sum
of the three denominators)
Data Collection Method: Administrative
Guidance for Reporting:
• This measure applies to individuals in the Project 1.4 Target
Population age 18 and older.
• Include all paid, suspended, pending, and denied claims.
• NCQA’s list of NDC codes for ACE Inhibitors/ARBs can be found
at:
http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS2015/HEDIS2
015NDCLicense/HEDIS2015FinalNDCLists.aspx
B. ELIGIBLE POPULATION
Age
Age 18 and older as of the last day of the measurement
period
PRIME Project 1.4 Patient Safety in the Ambulatory Care
SettingMetric Specification Manual V2.3
Return to Summary Table Page 18 of 19v2.3 6/30/16, DHCS
Approved
(Measure MPM-AD: Annual Monitoring for Patients on Persistent
Medications) (5)
Event/
Diagnosis
Individuals on persistent medications (i.e., Individuals who
received at least 180 treatment days of ambulatory medication in
the measurement year). Refer to Additional Eligible Population
Criteria for each rate.
Treatment days are the actual number of calendar days covered
with prescriptions within the measurement period (i.e., a
prescription of 90 days’ supply dispensed on first day of the last
month of the measurement year counts as 30 treatment days). Sum the
days’ supply for all medications and subtract any days’ supply that
extends beyond the last day of the measurement period.
Note: Medications dispensed in the year prior to the measurement
year must be counted toward the 180 treatment days.
C. ADMINISTRATIVE SPECIFICATION
Report as a total rate. The total rate is the sum of the three
numerators divided by the sum of the three denominators.
Rate 1: Annual Monitoring for Individuals on ACE Inhibitors or
ARBs
Additional Eligible Population Criteria
Individuals who received at least 180 treatment days of ACE
inhibitors or ARBs, during the measurement year. Refer to Table
MPM-A (which corresponds to NDC code Table CDC-L) to identify ACE
inhibitors and ARBs.
Individuals may switch therapy with any medication listed in
Table MPM-A during the measurement year and have the day’s supply
for those medications count toward the total 180 treatment days
(i.e., an individual who received 90 days of ACE inhibitors and 90
days of ARBs meets the denominator definition for rate 1).
Table MPM-A. ACE Inhibitors/ARBs
Description
Prescription
Angiotensin converting enzyme inhibitors
Benazepril Captopril Enalapril Fosinopril
Lisinopril Moexipril Perindopril Quinapril
Ramipril
Trandolapril
Angiotensin II
inhibitors
Azilsartan Candesartan Eprosartan Irbesartan
Losartan Olmesartan Telmisartan Valsartan
.
Description
Prescription
Antihypertensive combinations
Aliskiren-valsartan Amlodipine-benazepril Amlodipine-
hydrochlorothiazide-
valsartan
Amlodipine- hydrochlorothiazide- olmesartan
Amlodipine- olmesartan
Amlodipine- telmisartan
Amlodipine-valsartan
Azilsartan- chlorthalidone
Benazepril- hydrochlorothiazide
Candesartan- hydrochlorothiazide
Captopril- hydrochlorothiazide
Enalapril- hydrochlorothiazide
Eprosartan- hydrochlorothiazide
Fosinopril- hydrochlorothiazide
Hydrochlorothiazide- irbesartan
Hydrochlorothiazide- lisinopril
Hydrochlorothiazide
-losartan
Hydrochlorothiazide
-moexipril
Hydrochlorothiazide
-olmesartan
Hydrochlorothiazide
-quinapril
Hydrochlorothiazide
-telmisartan
Hydrochlorothiazide
-valsartan
Trandolapril- verapamil
Numerator
At least one serum potassium and a serum creatinine therapeutic
monitoring test in the measurement year. Any of the following
during the measurement year meet criteria:
•A lab panel test (Lab Panel Value Set)
•A serum potassium test (Serum Potassium Value Set) and a serum
creatinine test
(Serum Creatinine Value Set)
The tests do not need to occur on the same service date, only
within the measurement year.
Rate 2: Annual Monitoring for Individuals on Digoxin
Additional Eligible Population Criteria
Individuals who received at least 180 treatment days of digoxin
(Table MPM-B) during the measurement year.
Table MPM-B. Drugs to Identify Individuals on Digoxin
Description
Prescription
Inotropic agents
Digoxin
Numerator
At least one serum potassium, at least one serum creatinine, and
at least one serum
digoxin therapeutic monitoring test in the measurement year. Any
of the following during the measurement period meet criteria:
• A lab panel test (Lab Panel Value Set) and a serum digoxin
test (Digoxin Level Value
Set).
• A serum potassium test (Serum Potassium Value Set), and a
serum creatinine test
(Serum Creatinine Value Set) and a serum digoxin test (Digoxin
Level Value Set).
The tests do not need to occur on the same service date, only
within the measurement period.
Rate 3: Annual Monitoring for Individuals on Diuretics
Additional Eligible Population Criteria
Individuals who received at least 180 treatment days of a
diuretic (Table MPM-C), during the measurement year.
Individuals may switch therapy with any medication listed in
Table MPM-C during the measurement year and have the day’s supply
for those medications count toward the total 180 treatment
days.
Table MPM-C. Drugs to Identify Individuals on Diuretics
Description
Prescription
Antihypertensive combinations
Aliskiren-hydrochlorothiazide
Aliskiren-hydrochlorothiazide- amlodipine
Amiloride-hydrochlorothiazide
Amlodipine-hydrochlorothiazide- olmesartan
Amlodipine-hydrochlorothiazide- valsartan
Atenolol-chlorthalidone Azilsartan-chlorthalidone
Benazepril-hydrochlorothiazide Bendroflumethiazide-nadolol
Bisoprolol-hydrochlorothiazide Candesartan-hydrochlorothiazide
Captopril-hydrochlorothiazide Chlorthalidone-clonidine
Enalapril-hydrochlorothiazide
Eprosartan-hydrochlorothiazide Fosinopril-hydrochlorothiazide
Hydrochlorothiazide-irbesartan Hydrochlorothiazide-lisinopril
Hydrochlorothiazide-losartan Hydrochlorothiazide-methyldopa
Hydrochlorothiazide-metoprolol Hydrochlorothiazide-moexipril
Hydrochlorothiazide-olmesartan Hydrochlorothiazide-propranolol
Hydrochlorothiazide-quinapril Hydrochlorothiazide-
spironolactone
Hydrochlorothiazide-telmisartan Hydrochlorothiazide-triamterene
Hydrochlorothiazide-valsartan
Loop diuretics
Bumetanide
Ethacrynic acid
Furosemide
Torsemide
Potassium- sparing diuretics
Amiloride
Eplerenone
Spironolactone
Triamterene
Thiazide diuretics
Chlorothiazide Chlorthalidone Hydrochlorothiazide
Indapamide Methyclothiazide Metolazone
Numerator
At least one serum potassium and a serum creatinine therapeutic
monitoring test in the measurement period. Any of the following
during the measurement period meet criteria:
•A lab panel test (Lab Panel Value Set).
•A serum potassium test (Serum Potassium Value Set) and a serum
creatinine test
(Serum Creatinine Value Set).
The tests do not need to occur on the same service date, only
within the measurement period.
Exclusions (optional)
Exclude individuals from each eligible population rate who had
an inpatient (acute or non-acute) claim/ encounter during the
measurement period.
1.4.1 - Abnormal results follow-up: % of abnormal results with
appropriate and timely documentation and follow-upI.
BACKGROUNDMeasure Title: Abnormal Results Follow-UpMeasure
Description
% of abnormal ambulatory care results with appropriate and
timely documentation and follow-up for Potassium, INR, and
Mammograms.
Project(s)
1.4 Patient Safety in the Ambulatory Care Setting
Measure Steward Entity(/ies), Organization
Alameda Health System
II. REPORTING
Measure Description:
This measure assesses the percentage of patients 18 years of age
and older who received any of each of the following ambulatory care
tests and follow-up during the measurement period: At least 180
treatment days of ACE/ARB or Diuretic, at least one potassium
monitoring event, and follow-up appropriate to the result; warfarin
therapy for at least 56 days, at least one INR monitoring test
during each 56-day interval with active warfarin therapy, and
follow-up appropriate to the result; and/or was assessed for breast
cancer with a mammogram and received follow-up appropriate to the
resultant BIRADs assessment.
The metric will be reported as 3 individual rates.
Potassium: Appropriate Monitoring and Follow-up
This measure assesses the percentage of ambulatory care serum
potassium tests performed on patients 18 years of age and older who
received at least 180 treatment days of ACE, ARB or Diuretic
therapy during the measurement year, at least one potassium
monitoring event for the therapeutic agent in the measurement year,
and follow-up appropriate to the results of that potassium
monitoring event.
Numerator Statement:
This measure is calculated and reported as only one total
rate.
Measure Numerator
Number of denominator serum Potassium tests that have had
appropriate follow-up, as per the following:
· Potassium (K) 3.5 – 5.1 Normal range, no lab follow-up
· Potassium ≥3 and <3.5 Follow up lab in 4 weeks
· Potassium ≥5.2 and < 6 Follow up lab in 10 days
· Potassium <3 or ≥6 Documented as a critical lab value and
that the ordering clinician (or responsible delegate) has been
informed within 24 hours
Numerator Code/s (CPT, ICD10, other)
· Follow-up
· Date of Follow-up
· Date and time of documentation that ordering clinician has
been informed
Denominator Statement:
The number of serum potassium tests completed in the ambulatory
setting during the measurement year in PRIME Eligible Population
patients age 18 and older, as of the end of the measurement period,
who are on selected persistent medications (ACE Inhibitors/ARB or
Diuretics) for at least 180 days.
Denominator Codes: (CPT, ICD10, other)
· Patient ID
· Data of prescriptions
· Lab code
· Date of Lab result
· Lab Result
· Medications (NDC code sets): See Abnormal Result
Spreadsheet
Exclusion/s
Tests ordered from the emergency department or inpatient
setting. Tests ordered from urgent care settings that are located
within an emergency department may also be excluded.
Reporting Business Logic
[Pending]
Definitions as applicable
Ambulatory care tests/Ambulatory setting
Any of the referenced tests ordered from any primary care,
specialty care or urgent care setting. Tests may be ordered by
primary or specialty care providers.
Other Notes as applicable
Potassium ordering from Annual Monitoring for Patients on
Persistent Medications.
If follow-up serum Potassium tests are performed in the
ambulatory setting and are also outside the normal range, they too
will be will be included in the denominator, with subsequent
follow-up serum Potassium tests being included in the
numerator.
Measurement Period as applicable
DY 11: Final End of Year:
· July 1, 2015 through June 30, 2016
DY 12-DY 15:
· Interim Mid-Year: January 1, 20xx through December 31,
20xx
· Final End of Year: July 1, 20xx through June 30, 20xx
INR: Appropriate Monitoring and Follow-upMeasure Numerator
Number of denominator INR's that have had appropriate follow-up
as per the following:
· INR < 2 follow up with a new lab in 4 weeks
· INR 2-3.5No lab follow-up
· INR > 3.5 and <4.9 follow up with a new lab in 10
days
· INR >4.9 Documented as a critical lab value and that the
ordering clinician (or responsible delegate) has been informed
within 24 hours
Numerator Code/s (CPT, ICD10, other)
· Follow-up
· Date of Follow-up
· Date and time of documentation that ordering clinician has
been informed
Measure Denominator
The number of INR's completed in the ambulatory setting during
the measurement year for individuals in the Target Population, at
least 18 years of age as of the beginning of the measurement period
with warfarin therapy for at least 56 days during the measurement
period and who have at least one INR monitoring test during each
56-day interval with active warfarin therapy. Please Refer to Specs
for Metric NQF 0555 for all specifications necessary to calculate
the denominator for the INR portion of the Abnormal Results
Follow-up metric.
Denominator Code/s (CPT, ICD10, other)
· Date and time of index INR
· See NQF 0555 Please Refer to Specs for Metric NQF 0555
Exclusion/s
Individuals monitoring INR at home. Individuals who are in
long-term care during the measurement period.
INR tests ordered from the emergency department or inpatient
setting. INR tests ordered from urgent care settings that are
located within an emergency department may also be excluded.
Reporting Business Logic
Definitions as applicable
Ambulatory care tests/Ambulatory setting
Any of the referenced tests ordered from any primary care,
specialty care or urgent care setting. Tests may be ordered by
primary or specialty care providers.
Other Notes as applicable
If follow-up INR’s are performed in the ambulatory setting and
are also outside the normal range, they too will be will be
included in the denominator, with subsequent follow-up INR’s being
included in the numerator.
Measurement Period as applicable
DY 11: Final End of Year:
· July 1, 2015 through June 30, 2016
DY 12-DY 15:
· Interim Mid-Year: January 1, 20xx through December 31,
20xx
· Final End of Year: July 1, 20xx through June 30, 20xx
BIRADs Follow-upMeasure Numerator
Number of denominator mammograms that received appropriate
follow-up based on the results of the BIRAD assessment, as per the
following:
· BIRADS = 0 Recall for additional images or comparison with
prior mammograms within 30 days of index mammogram
· BIRADS = 1 or 2 Routine follow-up
· BIRADS = 3 6 month follow up study
Numerator Code/s (CPT, ICD10, other)
· Follow-up
· Date of Follow-up
Measure Denominator
Number of index mammograms performed PRIME Eligible Population
individuals during the measurement period as defined below under
“Measurement Period as applicable”
Denominator Code/s (CPT, ICD10, other)
· Patient ID
· Patient DOB
· Date of Mammogram result
· Mammogram BIRADS Assessment score
Exclusion/s
Any Mammogram with a result of BIRADS 4 or 5.
Mammograms ordered from the emergency department or inpatient
setting. Mammograms ordered from urgent care settings that are
located within an emergency department may also be excluded.
Reporting Business Logic
None
Definitions as applicable Ambulatory care tests/Ambulatory
setting
Any of mammograms ordered from any primary care, specialty care
or urgent care setting. Tests may be ordered by primary or
specialty care providers.
Other Notes as applicable
None
Measurement Period as applicable
DY 11: Final End of Year:
· BIRADS = 0 (30 day follow-up):
· Index Mammogram from July 1, 2015 to May 31, 2016
· Recall for additional images or comparison with prior
mammograms from July 1, 2015 through June 30, 2016
· BIRADS = 1 or 2 (1-2 year follow-up):
· Index Mammogram from July 1, 2013 to June 30, 2014
· Routine follow-up mammogram from July 1, 2015 to June 30,
2016
· BIRADS = 3 (6 month follow-up):
· Index Mammogram from January 1, 2015 to December 31, 2015
· Follow-up mammogram from July 1, 2015 to June 30, 2016
DY 12:
· Interim Mid-Year:
· BIRADS = 0 (30 day follow-up):
· Index Mammogram from January 1, 2016 to December 1, 2016
· Recall for additional images or comparison with prior
mammograms from January 1, 2016 through December 31, 2016
· BIRADS = 1 or 2 (1-2 year follow-up):
· Index Mammogram from January 1, 2014 through December 31,
2014
· Routine follow-up mammogram from January 1, 2016 to December
31, 2016
· BIRADS = 3 (6 month follow-up):
· Index Mammogram from July 1, 2015 to June 30, 2016
· Follow-up mammogram from January 1, 2016 to December 31,
2016
· Final End of Year: July 1, 20xx through June 30, 20xx
· BIRADS = 0 (30 day follow-up):
· Index Mammogram from July 1, 2016 to May 31, 2017
· Recall for additional images or comparison with prior
mammograms from July 1, 2016 through June 30, 2017
· BIRADS = 1 or 2 (1-2 year follow-up):
· Index Mammogram from July 1, 2014 to June 30, 2015
· Routine follow-up mammogram from July 1, 2016 to June 30,
2017
· BIRADS = 3 (6 month follow-up):
· Index Mammogram from January 1, 2016 to December 31, 2016
· Follow-up mammogram from July 1, 2016 to June 30, 2017
DY 13:
· Interim Mid-Year:
· BIRADS = 0 (30 day follow-up):
· Index Mammogram from January 1, 2017 to December 1, 2017
· Recall for additional images or comparison with prior
mammograms from January 1, 2017 through December 31, 2017
· BIRADS = 1 or 2 (1-2 year follow-up):
· Index Mammogram from January 1, 2015 through December 31,
2015
· Routine follow-up mammogram from January 1, 2017 to December
31, 2017
· BIRADS = 3 (6 month follow-up):
· Index Mammogram from July 1, 2016 to June 30, 2017
· Follow-up mammogram from January 1, 2017 to December 31,
2017
· Final End of Year:
· BIRADS = 0 (30 day follow-up):
· Index Mammogram from July 1, 2017 to May 31, 2018
· Recall for additional images or comparison with prior
mammograms from July 1, 2017 through June 30, 2018
· BIRADS = 1 or 2 (1-2 year follow-up):
· Index Mammogram from July 1, 2015 to June 30, 2016
· Routine follow-up mammogram from July 1, 2017 to June 30,
2018
· BIRADS = 3 (6 month follow-up):
· Index Mammogram from January 1, 2017 to December 31, 2017
· Follow-up mammogram from July 1, 2017 to June 30, 2018
DY 14:
· Interim Mid-Year:
· BIRADS = 0 (30 day follow-up):
· Index Mammogram from January 1, 2018 to December 1, 2018
· Recall for additional images or comparison with prior
mammograms from January 1, 2018 through December 31, 2018
· BIRADS = 1 or 2 (1-2 year follow-up):
· Index Mammogram from January 1, 2016 through December 31,
2016
· Routine follow-up mammogram from January 1, 2018 to December
31, 2018
· BIRADS = 3 (6 month follow-up):
· Index Mammogram from July 1, 2017 to June 30, 2018
· Follow-up mammogram from January 1, 2018 to December, 2018
· Final End of Year:
· BIRADS = 0 (30 day follow-up):
· Index Mammogram from July 1, 2018 to May 31, 2019
· Recall for additional images or comparison with prior
mammograms from July 1, 2018 through June 30, 2019
· BIRADS = 1 or 2 (1-2 year follow-up):
· Index Mammogram from July 1, 2016 to June 30, 2017
· Routine follow-up mammogram from July 1, 2018 to June 30,
2019
· BIRADS = 3 (6 month follow-up):
· Index Mammogram from January 1, 2018 to December 31, 2018
· Follow-up mammogram from July 1, 2018 to June 30, 2019
DY 15:
· Interim Mid-Year:
· BIRADS = 0 (30 day follow-up):
· Index Mammogram from January 1, 2019 to December 1, 2019
· Recall for additional images or comparison with prior
mammograms from January 1, 2019 through December 31, 2019
· BIRADS = 1 or 2 (1-2 year follow-up):
· Index Mammogram from January 1, 2017 through December 31,
2017
· Routine follow-up mammogram from January 1, 2019 to December
31, 2019
· BIRADS = 3 (6 month follow-up):
· Index Mammogram from July 1, 2018 to June 30, 2019
· Follow-up mammogram from January 1, 2019 to December 31,
2019
· Final End of Year:
· BIRADS = 0 (30 day follow-up):
· Index Mammogram from July 1, 2019 to May 31, 2020
· Recall for additional images or comparison with prior
mammograms from July 1, 2019 through June 30, 2020
· BIRADS = 1 or 2 (1-2 year follow-up):
· Index Mammogram from July 1, 2017 to June 30, 2018
· Routine follow-up mammogram from July 1, 2019 to June 30,
2020
· BIRADS = 3 (6 month follow-up):
· Index Mammogram from January 1, 2019 to December 31, 2019
· Follow-up mammogram from July 1, 2019 to June 30, 2020
III. RATIONALERationale for MeasureScientific Acceptability
1.4.3 - NQF 0555: INR Monitoring for Individuals on Warfarin
Brief Description
Percentage of individuals in the Project 1.4 Target Population
at least 18 years of age as of the beginning of the measurement
period with at least 56 days of warfarin therapy who receive an
International Normalized Ratio (INR) test during each 56-day
interval with warfarin
Numerator Statement: The number of individuals in the
denominator who have at least one INR monitoring test during each
56-day interval with active warfarin therapy
Time Period for Data: The time period of the data is defined as
any time during the measurement period (12 consecutive months).
Numerator Details: Individuals in the denominator who have at
least one INR test performed during each 56-day interval with
warfarin therapy, or 100% INR monitoring compliance, will be
counted in the numerator. Each 56-day interval with an INR testis
used to calculate the INR compliance rate for the individual. An
interval with a hospitalization of more than 48 hours is considered
an interval with an INR test.
INR Test: Prothrombin time, CPT 85610
“Warfarin usage” or “warfarin therapy” is determined by the
start date of the first prescription for warfarin up through the
start date of the last prescription for warfarin plus the days’
supply from the last claim.
Interval: 56 days
The first day of the first 56-day interval is the start date of
the first warfarin prescription, and the last day of the first
56-day interval is the start date of the first warfarin
prescription + 55. The subsequent 56-day interval starts on the day
after the first 56-day interval and ends 56 days following the
first 56-day interval, as long as this end date occurs within the
warfarin therapy time frame. This process continues until a
calculated 56-day interval end date does not occur within the
warfarin therapy time frame. If there are fewer than 56 days of
warfarin therapy remaining, those remaining days are not counted in
any interval in determining the numerator. Only full 56-day
intervals are used for calculating the numerator.
For individuals who died during the measurement year, set
warfarin therapy end date to be the death date of the
individual
Denominator Details
Project 1.4 Target Population
Active Ingredients by Class
Anticoagulants: warfarin
Note: The active ingredient is limited to oral formulations
only.
Denominator Exclusions
Individuals who are monitoring INR at home
Optional Exclusion Criteria
Individuals who are in long-term care (LTC) during the
measurement period
Denominator Exclusion Details:
Table 1. HCPCS Codes for INR Monitoring at Home
G0248 - DEMONSTRATE USE HOME INR MON
G0249 - PROVIDE TEST MATS & EQUIP HOME INR
G0250 - MD INR TEST REVIEW INTER MGMT
Stratification Details/Variables S.12.
Depending on the operational use of the measure, measure results
may be stratified by:
· State
· Plan
· ACOs*
· Physician Group**
· Age – Divided into six categories: 18-24, 25-44, 45-64, 65-74,
75-84, and 85+ years
· Race/Ethnicity
· Dual Eligibility Status
· New Warfarin User vs. Continuous Warfarin User: “New” users
are defined as those individuals with no warfarin prescriptions
during the 180 days prior to the first warfarin prescription in the
current measurement period.
· Diagnosis Indications for Warfarin: Atrial Fibrillation, Acute
Myocardial Infarction, Venous Thromboembolism, Stroke, Mechanical
Heart Valve
*ACO attribution methodology is based on where the beneficiary
is receiving the plurality of his/her primary care services and
subsequently assigned to the participating providers.
**See Calculation Algorithm/Measure Logic S.18 below for
physician group attribution methodology used for this measure.
For full measure specification, see NQF 0555 Measure Information
Form and Code Table
(*Outstanding for V2.0. Will be updated in future
version.Questions or feedback on metrics: complete survey)Page 1 of
9
#9 Abnormal Result
Innovative Metric_Codes.xlsx
ACE-IPRODUCTIDPRODUCTNDCPRODUCTTYPENAMEPROPRIETARYNAMEPROPRIETARYNAMESUFFIXNONPROPRIETARYNAMEDOSAGEFORMNAMEROUTENAMESTARTMARKETINGDATEENDMARKETINGDATEMARKETINGCATEGORYNAMEAPPLICATIONNUMBERLABELERNAMESUBSTANCENAMEACTIVE_NUMERATOR_STRENGTHACTIVE_INGRED_UNITPHARM_CLASSESDEASCHEDULE0006-0019_de13746c-75ab-4326-9f82-ae37a19b34850006-0019HUMAN
PRESCRIPTION
DRUGPRINIVILlisinoprilTABLETORAL19871229NDANDA019558Merck Sharp
& Dohme Corp.LISINOPRIL5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0006-0106_de13746c-75ab-4326-9f82-ae37a19b34850006-0106HUMAN
PRESCRIPTION
DRUGPRINIVILlisinoprilTABLETORAL19871229NDANDA019558Merck Sharp
& Dohme Corp.LISINOPRIL10mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0006-0207_de13746c-75ab-4326-9f82-ae37a19b34850006-0207HUMAN
PRESCRIPTION
DRUGPRINIVILlisinoprilTABLETORAL19871229NDANDA019558Merck Sharp
& Dohme Corp.LISINOPRIL20mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0054-0106_7ef5e23b-e5a0-441a-85d4-4b50a060ec9f0054-0106HUMAN
PRESCRIPTION
DRUGRamiprilRamiprilCAPSULEORAL20080618ANDAANDA077900Roxane
Laboratories, IncRAMIPRIL1.25mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0054-0107_7ef5e23b-e5a0-441a-85d4-4b50a060ec9f0054-0107HUMAN
PRESCRIPTION
DRUGRamiprilRamiprilCAPSULEORAL20080618ANDAANDA077900Roxane
Laboratories, IncRAMIPRIL2.5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0054-0108_7ef5e23b-e5a0-441a-85d4-4b50a060ec9f0054-0108HUMAN
PRESCRIPTION
DRUGRamiprilRamiprilCAPSULEORAL20080618ANDAANDA077900Roxane
Laboratories, IncRAMIPRIL5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0054-0109_7ef5e23b-e5a0-441a-85d4-4b50a060ec9f0054-0109HUMAN
PRESCRIPTION
DRUGRamiprilRamiprilCAPSULEORAL20080618ANDAANDA077900Roxane
Laboratories, IncRAMIPRIL10mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0054-0110_dc50c8a3-ab29-49d5-b71b-67afe91639e20054-0110HUMAN
PRESCRIPTION DRUGPerindopril ErbuminePerindopril
ErbumineTABLETORAL20091110ANDAANDA090072Roxane Laboratories,
Inc.PERINDOPRIL ERBUMINE2mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0054-0111_dc50c8a3-ab29-49d5-b71b-67afe91639e20054-0111HUMAN
PRESCRIPTION DRUGPerindopril ErbuminePerindopril
ErbumineTABLETORAL20091110ANDAANDA090072Roxane Laboratories,
Inc.PERINDOPRIL ERBUMINE4mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0054-0112_dc50c8a3-ab29-49d5-b71b-67afe91639e20054-0112HUMAN
PRESCRIPTION DRUGPerindopril ErbuminePerindopril
ErbumineTABLETORAL20091110ANDAANDA090072Roxane Laboratories,
Inc.PERINDOPRIL ERBUMINE8mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0071-0220_c1959c67-9f77-4421-94bd-add5cbe528f10071-0220HUMAN
PRESCRIPTION DRUGACCURETICquinapril hydrochloride and
hydrochlorothiazideTABLET, FILM
COATEDORAL19991228NDANDA020125Parke-Davis Div of Pfizer
IncQUINAPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE20; 12.5mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0071-0222_c1959c67-9f77-4421-94bd-add5cbe528f10071-0222HUMAN
PRESCRIPTION DRUGACCURETICquinapril hydrochloride and
hydrochlorothiazideTABLET, FILM
COATEDORAL19991228NDANDA020125Parke-Davis Div of Pfizer
IncQUINAPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE10; 12.5mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0071-0223_c1959c67-9f77-4421-94bd-add5cbe528f10071-0223HUMAN
PRESCRIPTION DRUGACCURETICquinapril hydrochloride and
hydrochlorothiazideTABLET, FILM
COATEDORAL19991228NDANDA020125Parke-Davis Div of Pfizer
IncQUINAPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE20; 25mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0071-0527_1a25662a-eb93-4ee5-9252-57013b42e4660071-0527HUMAN
PRESCRIPTION DRUGAccuprilquinapril hydrochlorideTABLET, FILM
COATEDORAL19911119NDANDA019885Parke-Davis Div of Pfizer
IncQUINAPRIL HYDROCHLORIDE5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0071-0530_1a25662a-eb93-4ee5-9252-57013b42e4660071-0530HUMAN
PRESCRIPTION DRUGAccuprilquinapril hydrochlorideTABLET, FILM
COATEDORAL19911119NDANDA019885Parke-Davis Div of Pfizer
IncQUINAPRIL HYDROCHLORIDE10mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0071-0532_1a25662a-eb93-4ee5-9252-57013b42e4660071-0532HUMAN
PRESCRIPTION DRUGAccuprilquinapril hydrochlorideTABLET, FILM
COATEDORAL19911119NDANDA019885Parke-Davis Div of Pfizer
IncQUINAPRIL HYDROCHLORIDE20mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0071-0535_1a25662a-eb93-4ee5-9252-57013b42e4660071-0535HUMAN
PRESCRIPTION DRUGAccuprilquinapril hydrochlorideTABLET, FILM
COATEDORAL19911119NDANDA019885Parke-Davis Div of Pfizer
IncQUINAPRIL HYDROCHLORIDE40mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0074-2278_1a25b900-57e1-87c3-6bd9-3832059650590074-2278HUMAN
PRESCRIPTION
DRUGMavikTrandolaprilTABLETORAL19960426NDANDA020528AbbVie
Inc.TRANDOLAPRIL1mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0074-2279_1a25b900-57e1-87c3-6bd9-3832059650590074-2279HUMAN
PRESCRIPTION
DRUGMavikTrandolaprilTABLETORAL19960426NDANDA020528AbbVie
Inc.TRANDOLAPRIL2mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0074-2280_1a25b900-57e1-87c3-6bd9-3832059650590074-2280HUMAN
PRESCRIPTION
DRUGMavikTrandolaprilTABLETORAL19960426NDANDA020528AbbVie
Inc.TRANDOLAPRIL4mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0074-3287_836a02e2-731d-1198-f739-3e3ff66042950074-3287HUMAN
PRESCRIPTION DRUGTarkaTrandolapril and Verapamil
HydrochlorideTABLET, FILM COATED, EXTENDED
RELEASEORAL19961022NDANDA020591AbbVie Inc.TRANDOLAPRIL; VERAPAMIL
HYDROCHLORIDE2; 180mg/1; mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Calcium Channel Antagonists [MoA],Calcium Channel Blocker
[EPC]0074-3288_836a02e2-731d-1198-f739-3e3ff66042950074-3288HUMAN
PRESCRIPTION DRUGTarkaTrandolapril and Verapamil
HydrochlorideTABLET, FILM COATED, EXTENDED
RELEASEORAL19961022NDANDA020591AbbVie Inc.TRANDOLAPRIL; VERAPAMIL
HYDROCHLORIDE1; 240mg/1; mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Calcium Channel Antagonists [MoA],Calcium Channel Blocker
[EPC]0074-3289_836a02e2-731d-1198-f739-3e3ff66042950074-3289HUMAN
PRESCRIPTION DRUGTarkaTrandolapril and Verapamil
HydrochlorideTABLET, FILM COATED, EXTENDED
RELEASEORAL19961022NDANDA020591AbbVie Inc.TRANDOLAPRIL; VERAPAMIL
HYDROCHLORIDE2; 240mg/1; mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Calcium Channel Antagonists [MoA],Calcium Channel Blocker
[EPC]0074-3290_836a02e2-731d-1198-f739-3e3ff66042950074-3290HUMAN
PRESCRIPTION DRUGTarkaTrandolapril and Verapamil
HydrochlorideTABLET, FILM COATED, EXTENDED
RELEASEORAL19961022NDANDA020591AbbVie Inc.TRANDOLAPRIL; VERAPAMIL
HYDROCHLORIDE4; 240mg/1; mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Calcium Channel Antagonists [MoA],Calcium Channel Blocker
[EPC]0078-0364_556066cf-974c-4020-94f6-d2b7410c746d0078-0364HUMAN
PRESCRIPTION DRUGLotrelamlodipine besylate and benazepril
hydrochlorideCAPSULEORAL19950303NDANDA020364Novartis
Pharmaceuticals CorporationAMLODIPINE BESYLATE; BENAZEPRIL
HYDROCHLORIDE10; 20mg/1; mg/1Calcium Channel Antagonists
[MoA],Dihydropyridine Calcium Channel Blocker
[EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0078-0379_556066cf-974c-4020-94f6-d2b7410c746d0078-0379HUMAN
PRESCRIPTION DRUGLotrelamlodipine besylate and benazepril
hydrochlorideCAPSULEORAL19950303NDANDA020364Novartis
Pharmaceuticals CorporationAMLODIPINE BESYLATE; BENAZEPRIL
HYDROCHLORIDE10; 40mg/1; mg/1Calcium Channel Antagonists
[MoA],Dihydropyridine Calcium Channel Blocker
[EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0078-0384_556066cf-974c-4020-94f6-d2b7410c746d0078-0384HUMAN
PRESCRIPTION DRUGLotrelamlodipine besylate and benazepril
hydrochlorideCAPSULEORAL19950303NDANDA020364Novartis
Pharmaceuticals CorporationAMLODIPINE BESYLATE; BENAZEPRIL
HYDROCHLORIDE5; 40mg/1; mg/1Calcium Channel Antagonists
[MoA],Dihydropyridine Calcium Channel Blocker
[EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0078-0404_556066cf-974c-4020-94f6-d2b7410c746d0078-0404HUMAN
PRESCRIPTION DRUGLotrelamlodipine besylate and benazepril
hydrochlorideCAPSULEORAL19950303NDANDA020364Novartis
Pharmaceuticals CorporationAMLODIPINE BESYLATE; BENAZEPRIL
HYDROCHLORIDE2.5; 10mg/1; mg/1Calcium Channel Antagonists
[MoA],Dihydropyridine Calcium Channel Blocker
[EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0078-0405_556066cf-974c-4020-94f6-d2b7410c746d0078-0405HUMAN
PRESCRIPTION DRUGLotrelamlodipine besylate and benazepril
hydrochlorideCAPSULEORAL19950303NDANDA020364Novartis
Pharmaceuticals CorporationAMLODIPINE BESYLATE; BENAZEPRIL
HYDROCHLORIDE5; 10mg/1; mg/1Calcium Channel Antagonists
[MoA],Dihydropyridine Calcium Channel Blocker
[EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0078-0406_556066cf-974c-4020-94f6-d2b7410c746d0078-0406HUMAN
PRESCRIPTION DRUGLotrelamlodipine besylate and benazepril
hydrochlorideCAPSULEORAL19950303NDANDA020364Novartis
Pharmaceuticals CorporationAMLODIPINE BESYLATE; BENAZEPRIL
HYDROCHLORIDE5; 20mg/1; mg/1Calcium Channel Antagonists
[MoA],Dihydropyridine Calcium Channel Blocker
[EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0091-3707_2c711a79-fc80-331d-e054-00144ff88e880091-3707HUMAN
PRESCRIPTION DRUGUnivascmoexipril hydrochlorideTABLET, FILM
COATEDORAL19950715NDANDA020312UCB, Inc.MOEXIPRIL
HYDROCHLORIDE7.5mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0093-0017_17a7d6c6-89ea-4293-9d90-a92e7c6f49560093-0017HUMAN
PRESCRIPTION DRUGMoexipril HydrochlorideMoexipril
HydrochlorideTABLET, FILM COATEDORAL20030508ANDAANDA076204Teva
Pharmaceuticals USA IncMOEXIPRIL HYDROCHLORIDE7.5mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors
[MoA]0093-0026_19803835-979a-436c-8a59-019bd9f1cf990093-0026HUMAN
PRESCRIPTION DRUGEnalapril MaleateEnalapril
MaleateTABLETORAL20000823ANDAANDA075479Teva Pharmaceuticals USA
IncENALAPRIL MALEATE2.5mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure
[PE]0093-0027_19803835-979a-436c-8a59-019bd9f1cf990093-0027HUMAN
PRESCRIPTION DRUGEnalapril MaleateEnalapril
MaleateTABLETORAL20000823ANDAANDA075479Teva Pharmaceuticals USA
IncENALAPRIL MALEATE5mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure
[PE]0093-0028_19803835-979a-436c-8a59-019bd9f1cf990093-0028HUMAN
PRESCRIPTION DRUGEnalapril MaleateEnalapril
MaleateTABLETORAL20000823ANDAANDA075479Teva Pharmaceuticals USA
IncENALAPRIL MALEATE10mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure
[PE]0093-0029_19803835-979a-436c-8a59-019bd9f1cf990093-0029HUMAN
PRESCRIPTION DRUGEnalapril MaleateEnalapril
MaleateTABLETORAL20000823ANDAANDA075479Teva Pharmaceuticals USA
IncENALAPRIL MALEATE20mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure
[PE]0093-1052_775cd8ad-6c18-4ed4-a84f-4213263b7dbd0093-1052HUMAN
PRESCRIPTION DRUGEnalapril Maleate and HydrochlorothiazideEnalapril
Maleate and
HydrochlorothiazideTABLETORAL2001091920160430ANDAANDA075727Teva
Pharmaceuticals USA IncENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE10;
25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0093-5124_d61feec5-cf0f-42ca-8f2e-85b3cb95de420093-5124HUMAN
PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril
HydrochlorideTABLET, COATEDORAL20040211ANDAANDA076211Teva
Pharmaceuticals USA IncBENAZEPRIL HYDROCHLORIDE5mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Decreased Blood Pressure
[PE]0093-5125_d61feec5-cf0f-42ca-8f2e-85b3cb95de420093-5125HUMAN
PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril
HydrochlorideTABLET, COATEDORAL20040211ANDAANDA076211Teva
Pharmaceuticals USA IncBENAZEPRIL HYDROCHLORIDE10mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Decreased Blood Pressure
[PE]0093-5126_d61feec5-cf0f-42ca-8f2e-85b3cb95de420093-5126HUMAN
PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril
HydrochlorideTABLET, COATEDORAL20040211ANDAANDA076211Teva
Pharmaceuticals USA IncBENAZEPRIL HYDROCHLORIDE20mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Decreased Blood Pressure
[PE]0093-5127_d61feec5-cf0f-42ca-8f2e-85b3cb95de420093-5127HUMAN
PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril
HydrochlorideTABLET, COATEDORAL20040211ANDAANDA076211Teva
Pharmaceuticals USA IncBENAZEPRIL HYDROCHLORIDE40mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Decreased Blood Pressure
[PE]0093-5150_17a7d6c6-89ea-4293-9d90-a92e7c6f49560093-5150HUMAN
PRESCRIPTION DRUGMoexipril HydrochlorideMoexipril
HydrochlorideTABLET, FILM COATEDORAL20030508ANDAANDA076204Teva
Pharmaceuticals USA IncMOEXIPRIL HYDROCHLORIDE15mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors
[MoA]0093-5213_7176f8ee-94b8-4bc0-bb0e-e659a9ff27350093-5213HUMAN
PRESCRIPTION DRUGMoexipril Hydrochloride and
HydrochlorothiazideMoexipril Hydrochloride and
HydrochlorothiazideTABLET, FILM
COATEDORAL20070307ANDAANDA076980Teva Pharmaceuticals USA
IncMOEXIPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE7.5; 12.5mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0093-5214_7176f8ee-94b8-4bc0-bb0e-e659a9ff27350093-5214HUMAN
PRESCRIPTION DRUGMoexipril Hydrochloride and
HydrochlorothiazideMoexipril Hydrochloride and
HydrochlorothiazideTABLET, FILM
COATEDORAL20070307ANDAANDA076980Teva Pharmaceuticals USA
IncMOEXIPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE15; 12.5mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0093-5215_7176f8ee-94b8-4bc0-bb0e-e659a9ff27350093-5215HUMAN
PRESCRIPTION DRUGMoexipril Hydrochloride and
HydrochlorothiazideMoexipril Hydrochloride and
HydrochlorothiazideTABLET, FILM
COATEDORAL20070307ANDAANDA076980Teva Pharmaceuticals USA
IncMOEXIPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE15; 25mg/1;
mg/1Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0093-7222_a733b7d3-d690-42ab-aa97-eadfee03e9760093-7222HUMAN
PRESCRIPTION DRUGFosinopril SodiumFosinopril
SodiumTABLETORAL20031201ANDAANDA076139Teva Pharmaceuticals USA
IncFOSINOPRIL SODIUM10mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0093-7223_a733b7d3-d690-42ab-aa97-eadfee03e9760093-7223HUMAN
PRESCRIPTION DRUGFosinopril SodiumFosinopril
SodiumTABLETORAL20031201ANDAANDA076139Teva Pharmaceuticals USA
IncFOSINOPRIL SODIUM20mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0093-7224_a733b7d3-d690-42ab-aa97-eadfee03e9760093-7224HUMAN
PRESCRIPTION DRUGFosinopril SodiumFosinopril
SodiumTABLETORAL20031201ANDAANDA076139Teva Pharmaceuticals USA
IncFOSINOPRIL SODIUM40mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0093-7325_89a9bdcd-51ba-4ad1-b417-7819b1d1bafa0093-7325HUMAN
PRESCRIPTION
DRUGTrandolaprilTrandolaprilTABLETORAL2007020720160229ANDAANDA077489Teva
Pharmaceuticals USA IncTRANDOLAPRIL1mg/1Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0093-7326_89a9bdcd-51ba-4ad1-b417-7819b1d1bafa0093-7326HUMAN
PRESCRIPTION
DRUGTrandolaprilTrandolaprilTABLETORAL2007020720160331ANDAANDA077489Teva
Pharmaceuticals USA IncTRANDOLAPRIL2mg/1Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0093-7327_89a9bdcd-51ba-4ad1-b417-7819b1d1bafa0093-7327HUMAN
PRESCRIPTION
DRUGTrandolaprilTrandolaprilTABLETORAL2007020720160831ANDAANDA077489Teva
Pharmaceuticals USA IncTRANDOLAPRIL4mg/1Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0093-7370_a01949e8-8e46-44d2-94db-79863663a25d0093-7370HUMAN
PRESCRIPTION DRUGAmlodipine and Benazepril HydrochlorideAmlodipine
and Benazepril HydrochlorideCAPSULEORAL20070518ANDAANDA077179Teva
Pharmaceuticals USA IncAMLODIPINE BESYLATE; BENAZEPRIL
HYDROCHLORIDE2.5; 10mg/1; mg/1Calcium Channel Antagonists
[MoA],Dihydropyridine Calcium Channel Blocker
[EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0093-7371_a01949e8-8e46-44d2-94db-79863663a25d0093-7371HUMAN
PRESCRIPTION DRUGAmlodipine and Benazepril HydrochlorideAmlodipine
and Benazepril HydrochlorideCAPSULEORAL20070518ANDAANDA077179Teva
Pharmaceuticals USA IncAMLODIPINE BESYLATE; BENAZEPRIL
HYDROCHLORIDE5; 10mg/1; mg/1Calcium Channel Antagonists
[MoA],Dihydropyridine Calcium Channel Blocker
[EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0093-7372_a01949e8-8e46-44d2-94db-79863663a25d0093-7372HUMAN
PRESCRIPTION DRUGAmlodipine and Benazepril HydrochlorideAmlodipine
and Benazepril HydrochlorideCAPSULEORAL20070518ANDAANDA077179Teva
Pharmaceuticals USA IncAMLODIPINE BESYLATE; BENAZEPRIL
HYDROCHLORIDE5; 20mg/1; mg/1Calcium Channel Antagonists
[MoA],Dihydropyridine Calcium Channel Blocker
[EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0093-7373_a01949e8-8e46-44d2-94db-79863663a25d0093-7373HUMAN
PRESCRIPTION DRUGAmlodipine and Benazepril HydrochlorideAmlodipine
and Benazepril HydrochlorideCAPSULEORAL20070518ANDAANDA077179Teva
Pharmaceuticals USA IncAMLODIPINE BESYLATE; BENAZEPRIL
HYDROCHLORIDE10; 20mg/1; mg/1Calcium Channel Antagonists
[MoA],Dihydropyridine Calcium Channel Blocker
[EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0093-7436_3bc351c7-2578-485c-8f80-bef09a288d410093-7436HUMAN
PRESCRIPTION
DRUGRamiprilRamiprilCAPSULEORAL2008062420160731ANDAANDA077470Teva
Pharmaceuticals USA IncRAMIPRIL2.5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0093-7437_3bc351c7-2578-485c-8f80-bef09a288d410093-7437HUMAN
PRESCRIPTION
DRUGRamiprilRamiprilCAPSULEORAL2008062420160331ANDAANDA077470Teva
Pharmaceuticals USA IncRAMIPRIL5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0093-7438_3bc351c7-2578-485c-8f80-bef09a288d410093-7438HUMAN
PRESCRIPTION
DRUGRamiprilRamiprilCAPSULEORAL2008062420160331ANDAANDA077470Teva
Pharmaceuticals USA IncRAMIPRIL10mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0093-7670_a01949e8-8e46-44d2-94db-79863663a25d0093-7670HUMAN
PRESCRIPTION DRUGAmlodipine and Benazepril HydrochlorideAmlodipine
and Benazepril HydrochlorideCAPSULEORAL20110720ANDAANDA077179Teva
Pharmaceuticals USA IncAMLODIPINE BESYLATE; BENAZEPRIL
HYDROCHLORIDE5; 40mg/1; mg/1Calcium Channel Antagonists
[MoA],Dihydropyridine Calcium Channel Blocker
[EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0093-7671_a01949e8-8e46-44d2-94db-79863663a25d0093-7671HUMAN
PRESCRIPTION DRUGAmlodipine and Benazepril HydrochlorideAmlodipine
and Benazepril HydrochlorideCAPSULEORAL20110720ANDAANDA077179Teva
Pharmaceuticals USA IncAMLODIPINE BESYLATE; BENAZEPRIL
HYDROCHLORIDE10; 40mg/1; mg/1Calcium Channel Antagonists
[MoA],Dihydropyridine Calcium Channel Blocker
[EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting
Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0143-1171_0eb938d3-4faa-4bd9-96bc-ca8b95a80e390143-1171HUMAN
PRESCRIPTION
DRUGCaptoprilCaptoprilTABLETORAL19960213ANDAANDA074505West-Ward
Pharmaceuticals CorpCAPTOPRIL12.5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-1172_0eb938d3-4faa-4bd9-96bc-ca8b95a80e390143-1172HUMAN
PRESCRIPTION
DRUGCaptoprilCaptoprilTABLETORAL19960213ANDAANDA074505West-Ward
Pharmaceuticals CorpCAPTOPRIL25mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-1173_0eb938d3-4faa-4bd9-96bc-ca8b95a80e390143-1173HUMAN
PRESCRIPTION
DRUGCaptoprilCaptoprilTABLETORAL19960213ANDAANDA074505West-Ward
Pharmaceuticals CorpCAPTOPRIL50mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-1174_0eb938d3-4faa-4bd9-96bc-ca8b95a80e390143-1174HUMAN
PRESCRIPTION
DRUGCaptoprilCaptoprilTABLETORAL19960213ANDAANDA074505West-Ward
Pharmaceuticals CorpCAPTOPRIL100mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-1262_ebb57b71-8e07-4997-b865-5584555470be0143-1262HUMAN
PRESCRIPTION DRUGLisinopril with HydrochlorothiazideLisinopril and
HydrochlorothiazideTABLETORAL20020708ANDAANDA076265West-Ward
Pharmaceuticals CorpHYDROCHLOROTHIAZIDE; LISINOPRIL12.5; 10mg/1;
mg/1Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-1263_ebb57b71-8e07-4997-b865-5584555470be0143-1263HUMAN
PRESCRIPTION DRUGLisinopril with HydrochlorothiazideLisinopril and
HydrochlorothiazideTABLETORAL20020708ANDAANDA076265West-Ward
Pharmaceuticals CorpHYDROCHLOROTHIAZIDE; LISINOPRIL12.5; 20mg/1;
mg/1Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-1264_ebb57b71-8e07-4997-b865-5584555470be0143-1264HUMAN
PRESCRIPTION DRUGLisinopril with HydrochlorothiazideLisinopril and
HydrochlorothiazideTABLETORAL20020708ANDAANDA076265West-Ward
Pharmaceuticals CorpHYDROCHLOROTHIAZIDE; LISINOPRIL25; 20mg/1;
mg/1Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-1266_2696dc8a-b5e1-48cf-8118-976b92f0433d0143-1266HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA076063West-Ward
Pharmaceuticals CorpLISINOPRIL5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-1267_2696dc8a-b5e1-48cf-8118-976b92f0433d0143-1267HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA076063West-Ward
Pharmaceuticals CorpLISINOPRIL10mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-1268_2696dc8a-b5e1-48cf-8118-976b92f0433d0143-1268HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA076063West-Ward
Pharmaceuticals CorpLISINOPRIL20mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-1270_2696dc8a-b5e1-48cf-8118-976b92f0433d0143-1270HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA076063West-Ward
Pharmaceuticals CorpLISINOPRIL40mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-9713_662060b3-7bd7-436e-8b24-b0b99ed2b9060143-9713HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20130213ANDAANDA076063West-Ward
Pharmaceuticals CorpLISINOPRIL20mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-9714_662060b3-7bd7-436e-8b24-b0b99ed2b9060143-9714HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20130213ANDAANDA076063West-Ward
Pharmaceuticals CorpLISINOPRIL10mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0143-9715_662060b3-7bd7-436e-8b24-b0b99ed2b9060143-9715HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20130213ANDAANDA076063West-Ward
Pharmaceuticals CorpLISINOPRIL5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0172-3757_b50132eb-d135-40d4-9d8b-7527952ef8df0172-3757HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA075752IVAX
Pharmaceuticals, Inc.LISINOPRIL2.5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0172-3758_b50132eb-d135-40d4-9d8b-7527952ef8df0172-3758HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA075752IVAX
Pharmaceuticals, Inc.LISINOPRIL5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0172-3759_b50132eb-d135-40d4-9d8b-7527952ef8df0172-3759HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA075752IVAX
Pharmaceuticals, Inc.LISINOPRIL10mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0172-3760_b50132eb-d135-40d4-9d8b-7527952ef8df0172-3760HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA075752IVAX
Pharmaceuticals, Inc.LISINOPRIL20mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0172-3761_b50132eb-d135-40d4-9d8b-7527952ef8df0172-3761HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA075752IVAX
Pharmaceuticals, Inc.LISINOPRIL40mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0172-3762_b50132eb-d135-40d4-9d8b-7527952ef8df0172-3762HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA075752IVAX
Pharmaceuticals, Inc.LISINOPRIL30mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0172-5032_77ab08d3-f07f-4c75-b70a-f4c2c7c8645e0172-5032HUMAN
PRESCRIPTION DRUGLisinopril and HydrochlorothiazideLisinopril and
HydrochlorothiazideTABLETORAL20020701ANDAANDA075776IVAX
Pharmaceuticals, Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE20; 25mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0172-5033_77ab08d3-f07f-4c75-b70a-f4c2c7c8645e0172-5033HUMAN
PRESCRIPTION DRUGLisinopril and HydrochlorothiazideLisinopril and
HydrochlorothiazideTABLETORAL20020701ANDAANDA075776IVAX
Pharmaceuticals, Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE10; 12.5mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0172-5034_77ab08d3-f07f-4c75-b70a-f4c2c7c8645e0172-5034HUMAN
PRESCRIPTION DRUGLisinopril and HydrochlorothiazideLisinopril and
HydrochlorothiazideTABLETORAL20020701ANDAANDA075776IVAX
Pharmaceuticals, Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE20; 12.5mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0179-0135_10055ce4-847f-456b-949b-b8697a318d9f0179-0135HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20130805ANDAANDA077321KAISER
FOUNDATION HOSPITALSLISINOPRIL2.5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0179-1984_10055ce4-847f-456b-949b-b8697a318d9f0179-1984HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20081103ANDAANDA077321KAISER
FOUNDATION HOSPITALSLISINOPRIL40mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0179-1985_10055ce4-847f-456b-949b-b8697a318d9f0179-1985HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20081103ANDAANDA077321KAISER
FOUNDATION HOSPITALSLISINOPRIL20mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0179-1988_10055ce4-847f-456b-949b-b8697a318d9f0179-1988HUMAN
PRESCRIPTION
DRUGLisinoprilLisinoprilTABLETORAL20081103ANDAANDA077321KAISER
FOUNDATION HOSPITALSLISINOPRIL5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0025_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0025HUMAN
PRESCRIPTION
DRUGlisinoprillisinoprilTABLETORAL2002070120170930ANDAANDA075994Eon
Labs, Inc.LISINOPRIL2.5mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0041_100a257a-261b-411e-8197-dac277df9d530185-0041HUMAN
PRESCRIPTION DRUGFosinopril SodiumFosinopril
SodiumTABLETORAL20040423ANDAANDA076483Eon Labs, Inc.FOSINOPRIL
SODIUM10mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0042_100a257a-261b-411e-8197-dac277df9d530185-0042HUMAN
PRESCRIPTION DRUGFosinopril SodiumFosinopril
SodiumTABLETORAL20040423ANDAANDA076483Eon Labs, Inc.FOSINOPRIL
SODIUM20mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0047_100a257a-261b-411e-8197-dac277df9d530185-0047HUMAN
PRESCRIPTION DRUGFosinopril SodiumFosinopril
SodiumTABLETORAL20040423ANDAANDA076483Eon Labs, Inc.FOSINOPRIL
SODIUM40mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0053_937c8aa3-b2bf-438a-996f-53d2e455cbc30185-0053HUMAN
PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril
HydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076402Eon Labs,
Inc.BENAZEPRIL HYDROCHLORIDE10mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0185-0101_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0101HUMAN
PRESCRIPTION
DRUGlisinoprillisinoprilTABLETORAL2002070120171130ANDAANDA075994Eon
Labs, Inc.LISINOPRIL10mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0102_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0102HUMAN
PRESCRIPTION
DRUGlisinoprillisinoprilTABLETORAL2002070120171231ANDAANDA075994Eon
Labs, Inc.LISINOPRIL20mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0103_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0103HUMAN
PRESCRIPTION
DRUGlisinoprillisinoprilTABLETORAL2002070120171130ANDAANDA075994Eon
Labs, Inc.LISINOPRIL30mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0104_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0104HUMAN
PRESCRIPTION
DRUGlisinoprillisinoprilTABLETORAL2002070120171130ANDAANDA075994Eon
Labs, Inc.LISINOPRIL40mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0152_c057cfdf-3bfe-419f-9aeb-bf266ac4376f0185-0152HUMAN
PRESCRIPTION DRUGLisinopril and HydrochlorothiazideLisinopril and
HydrochlorothiazideTABLETORAL20020702ANDAANDA076262Eon Labs,
Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE20; 12.5mg/1; mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0185-0173_c057cfdf-3bfe-419f-9aeb-bf266ac4376f0185-0173HUMAN
PRESCRIPTION DRUGLisinopril and HydrochlorothiazideLisinopril and
HydrochlorothiazideTABLETORAL20020701ANDAANDA076262Eon Labs,
Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE20; 25mg/1; mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0185-0211_1f4a8d87-5394-4a23-b951-19f708af13670185-0211HUMAN
PRESCRIPTION DRUGBenazepril Hydrochloride and
HydrochlorothiazideBenazepril Hydrochloride and
HydrochlorothiazideTABLET, FILM COATEDORAL20040211ANDAANDA076631Eon
Labs, Inc.BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE20;
12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0185-0236_1f4a8d87-5394-4a23-b951-19f708af13670185-0236HUMAN
PRESCRIPTION DRUGBenazepril Hydrochloride and
HydrochlorothiazideBenazepril Hydrochloride and
HydrochlorothiazideTABLET, FILM COATEDORAL20150317ANDAANDA076631Eon
Labs, Inc.BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE5; 6.25mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0185-0277_1f4a8d87-5394-4a23-b951-19f708af13670185-0277HUMAN
PRESCRIPTION DRUGBenazepril Hydrochloride and
HydrochlorothiazideBenazepril Hydrochloride and
HydrochlorothiazideTABLET, FILM COATEDORAL20040211ANDAANDA076631Eon
Labs, Inc.BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE20; 25mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0185-0325_1f4a8d87-5394-4a23-b951-19f708af13670185-0325HUMAN
PRESCRIPTION DRUGBenazepril Hydrochloride and
HydrochlorothiazideBenazepril Hydrochloride and
HydrochlorothiazideTABLET, FILM COATEDORAL20140404ANDAANDA076631Eon
Labs, Inc.BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE10;
12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0185-0341_114dc847-8ad5-47c2-ad22-6efd5b73f9a60185-0341HUMAN
PRESCRIPTION DRUGFosinopril Sodium and
HydrochlorothiazideFosinopril Sodium and
HydrochlorothiazideTABLETORAL20050928ANDAANDA076961Eon Labs,
Inc.FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE10; 12.5mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0185-0342_114dc847-8ad5-47c2-ad22-6efd5b73f9a60185-0342HUMAN
PRESCRIPTION DRUGFosinopril Sodium and
HydrochlorothiazideFosinopril Sodium and
HydrochlorothiazideTABLETORAL20050928ANDAANDA076961Eon Labs,
Inc.FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE20; 12.5mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0185-0505_937c8aa3-b2bf-438a-996f-53d2e455cbc30185-0505HUMAN
PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril
HydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076402Eon Labs,
Inc.BENAZEPRIL HYDROCHLORIDE5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0185-0602_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0602HUMAN
PRESCRIPTION
DRUGlisinoprillisinoprilTABLETORAL20151221ANDAANDA075994Eon Labs,
Inc.LISINOPRIL2.5mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0610_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0610HUMAN
PRESCRIPTION
DRUGlisinoprillisinoprilTABLETORAL20150521ANDAANDA075994Eon Labs,
Inc.LISINOPRIL10mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0620_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0620HUMAN
PRESCRIPTION
DRUGlisinoprillisinoprilTABLETORAL20150523ANDAANDA075994Eon Labs,
Inc.LISINOPRIL20mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0630_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0630HUMAN
PRESCRIPTION
DRUGlisinoprillisinoprilTABLETORAL20150819ANDAANDA075994Eon Labs,
Inc.LISINOPRIL30mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0640_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0640HUMAN
PRESCRIPTION
DRUGlisinoprillisinoprilTABLETORAL20150609ANDAANDA075994Eon Labs,
Inc.LISINOPRIL40mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-0820_937c8aa3-b2bf-438a-996f-53d2e455cbc30185-0820HUMAN
PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril
HydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076402Eon Labs,
Inc.BENAZEPRIL HYDROCHLORIDE20mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0185-5400_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-5400HUMAN
PRESCRIPTION
DRUGlisinoprillisinoprilTABLETORAL2002070120171130ANDAANDA075994Eon
Labs, Inc.LISINOPRIL5mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0185-7100_c057cfdf-3bfe-419f-9aeb-bf266ac4376f0185-7100HUMAN
PRESCRIPTION DRUGLisinopril and HydrochlorothiazideLisinopril and
HydrochlorothiazideTABLETORAL20020701ANDAANDA076262Eon Labs,
Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE10; 12.5mg/1; mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0187-0140_842ca03b-e32e-4abe-8bbd-13eb94eb62740187-0140HUMAN
PRESCRIPTION DRUGVasotecEnalapril
MaleateTABLETORAL19880726NDANDA018998Valeant Pharmaceuticals North
America LLCENALAPRIL MALEATE2.5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0187-0141_842ca03b-e32e-4abe-8bbd-13eb94eb62740187-0141HUMAN
PRESCRIPTION DRUGVasotecEnalapril
MaleateTABLETORAL19851224NDANDA018998Valeant Pharmaceuticals North
America LLCENALAPRIL MALEATE5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0187-0142_842ca03b-e32e-4abe-8bbd-13eb94eb62740187-0142HUMAN
PRESCRIPTION DRUGVasotecEnalapril
MaleateTABLETORAL19851224NDANDA018998Valeant Pharmaceuticals North
America LLCENALAPRIL MALEATE10mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0187-0143_842ca03b-e32e-4abe-8bbd-13eb94eb62740187-0143HUMAN
PRESCRIPTION DRUGVasotecEnalapril
MaleateTABLETORAL19851224NDANDA018998Valeant Pharmaceuticals North
America LLCENALAPRIL MALEATE20mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure
[PE]0187-0146_0b8c532e-e758-447d-9087-ff0e3bf9df3f0187-0146HUMAN
PRESCRIPTION DRUGVasereticenalapril maleate and
hydrochlorothiazideTABLETORAL19861031NDANDA019221Valeant
Pharmaceuticals North America LLCENALAPRIL MALEATE;
HYDROCHLOROTHIAZIDE10; 25mg/1; mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA],Decreased Blood Pressure [PE],Increased Diuresis
[PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0310-0130_65d33be9-0f8c-4651-8955-ff66103f7d1f0310-0130HUMAN
PRESCRIPTION
DRUGZESTRILLisinoprilTABLETORAL20091111NDANDA019777AstraZeneca
Pharmaceuticals LPLISINOPRIL5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0310-0131_65d33be9-0f8c-4651-8955-ff66103f7d1f0310-0131HUMAN
PRESCRIPTION
DRUGZESTRILLisinoprilTABLETORAL20090828NDANDA019777AstraZeneca
Pharmaceuticals LPLISINOPRIL10mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0310-0132_65d33be9-0f8c-4651-8955-ff66103f7d1f0310-0132HUMAN
PRESCRIPTION
DRUGZESTRILLisinoprilTABLETORAL20090513NDANDA019777AstraZeneca
Pharmaceuticals LPLISINOPRIL20mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0310-0133_65d33be9-0f8c-4651-8955-ff66103f7d1f0310-0133HUMAN
PRESCRIPTION
DRUGZESTRILLisinoprilTABLETORAL20100922NDANDA019777AstraZeneca
Pharmaceuticals LPLISINOPRIL30mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0310-0134_65d33be9-0f8c-4651-8955-ff66103f7d1f0310-0134HUMAN
PRESCRIPTION
DRUGZESTRILLisinoprilTABLETORAL20100326NDANDA019777AstraZeneca
Pharmaceuticals LPLISINOPRIL40mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0310-0135_65d33be9-0f8c-4651-8955-ff66103f7d1f0310-0135HUMAN
PRESCRIPTION
DRUGZESTRILLisinoprilTABLETORAL20110902NDANDA019777AstraZeneca
Pharmaceuticals LPLISINOPRIL2.5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0310-0141_b0a1ece1-2539-4d34-ac8f-f933b04b0b7f0310-0141HUMAN
PRESCRIPTION DRUGZESTORETICLisinopril and
HydrochlorothiazideTABLETORAL20100615NDANDA019888AstraZeneca
Pharmaceuticals LPLISINOPRIL; HYDROCHLOROTHIAZIDE10; 12.5mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0310-0142_b0a1ece1-2539-4d34-ac8f-f933b04b0b7f0310-0142HUMAN
PRESCRIPTION DRUGZESTORETICLisinopril and
HydrochlorothiazideTABLETORAL20110509NDANDA019888AstraZeneca
Pharmaceuticals LPLISINOPRIL; HYDROCHLOROTHIAZIDE20; 12.5mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0310-0145_b0a1ece1-2539-4d34-ac8f-f933b04b0b7f0310-0145HUMAN
PRESCRIPTION DRUGZESTORETICLisinopril and
HydrochlorothiazideTABLETORAL20100727NDANDA019888AstraZeneca
Pharmaceuticals LPLISINOPRIL; HYDROCHLOROTHIAZIDE20; 25mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0378-0081_3f830175-e2d8-410d-b25a-49e4cc3c97e40378-0081HUMAN
PRESCRIPTION DRUGCaptopril and Hydrochlorothiazidecaptopril and
hydrochlorothiazideTABLETORAL19971229ANDAANDA074896Mylan
Phamaceuticals Inc.CAPTOPRIL; HYDROCHLOROTHIAZIDE25; 15mg/1;
mg/1Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0378-0083_3f830175-e2d8-410d-b25a-49e4cc3c97e40378-0083HUMAN
PRESCRIPTION DRUGCaptopril and Hydrochlorothiazidecaptopril and
hydrochlorothiazideTABLETORAL19971229ANDAANDA074896Mylan
Phamaceuticals Inc.CAPTOPRIL; HYDROCHLOROTHIAZIDE25; 25mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0378-0084_3f830175-e2d8-410d-b25a-49e4cc3c97e40378-0084HUMAN
PRESCRIPTION DRUGCaptopril and Hydrochlorothiazidecaptopril and
hydrochlorothiazideTABLETORAL19971229ANDAANDA074896Mylan
Phamaceuticals Inc.CAPTOPRIL; HYDROCHLOROTHIAZIDE50; 15mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0378-0086_3f830175-e2d8-410d-b25a-49e4cc3c97e40378-0086HUMAN
PRESCRIPTION DRUGCaptopril and Hydrochlorothiazidecaptopril and
hydrochlorothiazideTABLETORAL19971229ANDAANDA074896Mylan
Phamaceuticals Inc.CAPTOPRIL; HYDROCHLOROTHIAZIDE50; 25mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0378-0441_33b1c6ed-b367-4907-b3ae-e1b4911a12c80378-0441HUMAN
PRESCRIPTION DRUGBenazepril Hydrochloridebenazepril
hydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076430Mylan
Pharmaceuticals Inc.BENAZEPRIL HYDROCHLORIDE5mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Decreased Blood Pressure
[PE]0378-0443_33b1c6ed-b367-4907-b3ae-e1b4911a12c80378-0443HUMAN
PRESCRIPTION DRUGBenazepril Hydrochloridebenazepril
hydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076430Mylan
Pharmaceuticals Inc.BENAZEPRIL HYDROCHLORIDE10mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Decreased Blood Pressure
[PE]0378-0444_33b1c6ed-b367-4907-b3ae-e1b4911a12c80378-0444HUMAN
PRESCRIPTION DRUGBenazepril Hydrochloridebenazepril
hydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076430Mylan
Pharmaceuticals Inc.BENAZEPRIL HYDROCHLORIDE20mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Decreased Blood Pressure
[PE]0378-0447_33b1c6ed-b367-4907-b3ae-e1b4911a12c80378-0447HUMAN
PRESCRIPTION DRUGBenazepril Hydrochloridebenazepril
hydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076430Mylan
Pharmaceuticals Inc.BENAZEPRIL HYDROCHLORIDE40mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Decreased Blood Pressure
[PE]0378-0542_b06d635b-9da5-4f4b-8f58-f2850342916f0378-0542HUMAN
PRESCRIPTION DRUGQuinapril Hydrochloride and
Hydrochlorothiazidequinapril hydrochloride and
hydrochlorothiazideTABLET, FILM
COATEDORAL20070226ANDAANDA077093Mylan Pharmaceuticals Inc.QUINAPRIL
HYDROCHLORIDE; HYDROCHLOROTHIAZIDE10; 12.5mg/1; mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0378-0543_b06d635b-9da5-4f4b-8f58-f2850342916f0378-0543HUMAN
PRESCRIPTION DRUGQuinapril Hydrochloride and
Hydrochlorothiazidequinapril hydrochloride and
hydrochlorothiazideTABLET, FILM
COATEDORAL20070226ANDAANDA077093Mylan Pharmaceuticals Inc.QUINAPRIL
HYDROCHLORIDE; HYDROCHLOROTHIAZIDE20; 12.5mg/1; mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0378-0544_b06d635b-9da5-4f4b-8f58-f2850342916f0378-0544HUMAN
PRESCRIPTION DRUGQuinapril Hydrochloride and
Hydrochlorothiazidequinapril hydrochloride and
hydrochlorothiazideTABLET, FILM
COATEDORAL20070226ANDAANDA077093Mylan Pharmaceuticals Inc.QUINAPRIL
HYDROCHLORIDE; HYDROCHLOROTHIAZIDE20; 25mg/1; mg/1Angiotensin
Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme
Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0378-0712_77f1b18a-33a2-42bb-acde-c933ad85b8380378-0712HUMAN
PRESCRIPTION DRUGEnalapril Maleate and Hydrochlorothiazideenalapril
maleate and
hydrochlorothiazideTABLETORAL20010919ANDAANDA075624Mylan
Pharmaceuticals Inc.ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE5;
12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0378-0723_77f1b18a-33a2-42bb-acde-c933ad85b8380378-0723HUMAN
PRESCRIPTION DRUGEnalapril Maleate and Hydrochlorothiazideenalapril
maleate and
hydrochlorothiazideTABLETORAL20010919ANDAANDA075624Mylan
Pharmaceuticals Inc.ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE10;
25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic
[EPC],Thiazides
[Chemical/Ingredient]0378-1012_bc926c3f-d649-40f1-98cf-cea0ad60e6ab0378-1012HUMAN
PRESCRIPTION DRUGLisinopril and Hydrochlorothiazidelisinopril and
hydrochlorothiazideTABLETORAL20140904ANDAANDA076113Mylan
Pharmaceuticals Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE10; 12.5mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0378-1051_46369476-5900-4a51-994b-700c3cd89d310378-1051HUMAN
PRESCRIPTION DRUGEnalapril Maleateenalapril
maleateTABLETORAL20000822ANDAANDA075480Mylan Pharmaceuticals
Inc.ENALAPRIL MALEATE2.5mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure
[PE]0378-1052_46369476-5900-4a51-994b-700c3cd89d310378-1052HUMAN
PRESCRIPTION DRUGEnalapril MaleateEnalapril
MaleateTABLETORAL20000822ANDAANDA075480Mylan Pharmaceuticals
Inc.ENALAPRIL MALEATE5mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure
[PE]0378-1053_46369476-5900-4a51-994b-700c3cd89d310378-1053HUMAN
PRESCRIPTION DRUGEnalapril MaleateEnalapril
MaleateTABLETORAL20000822ANDAANDA075480Mylan Pharmaceuticals
Inc.ENALAPRIL MALEATE10mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure
[PE]0378-1054_46369476-5900-4a51-994b-700c3cd89d310378-1054HUMAN
PRESCRIPTION DRUGEnalapril MaleateEnalapril
MaleateTABLETORAL20000822ANDAANDA075480Mylan Pharmaceuticals
Inc.ENALAPRIL MALEATE20mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased
Blood Pressure
[PE]0378-2012_bc926c3f-d649-40f1-98cf-cea0ad60e6ab0378-2012HUMAN
PRESCRIPTION DRUGLisinopril and Hydrochlorothiazidelisinopril and
hydrochlorothiazideTABLETORAL20140904ANDAANDA076113Mylan
Pharmaceuticals Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE20; 12.5mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0378-2025_bc926c3f-d649-40f1-98cf-cea0ad60e6ab0378-2025HUMAN
PRESCRIPTION DRUGLisinopril and Hydrochlorothiazidelisinopril and
hydrochlorothiazideTABLETORAL20140904ANDAANDA076113Mylan
Pharmaceuticals Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE20; 25mg/1;
mg/1Angiotensin Converting Enzyme Inhibitor
[EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased
Diuresis [PE],Thiazide Diuretic [EPC],Thiazides
[Chemical/Ingredient]0378-2072_9195f48c-59af-471a-8522-1a53845157670378-2072HUMAN
PRESCRIPTION
DRUGLisinoprillisinoprilTABLETORAL20020701ANDAANDA076071Mylan
Pharmaceuticals Inc.LISINOPRIL2.5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0378-2073_9195f48c-59af-471a-8522-1a53845157670378-2073HUMAN
PRESCRIPTION
DRUGLisinoprillisinoprilTABLETORAL20020701ANDAANDA076071Mylan
Pharmaceuticals Inc.LISINOPRIL5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0378-2074_9195f48c-59af-471a-8522-1a53845157670378-2074HUMAN
PRESCRIPTION
DRUGLisinoprillisinoprilTABLETORAL20020701ANDAANDA076071Mylan
Pharmaceuticals Inc.LISINOPRIL10mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0378-2075_9195f48c-59af-471a-8522-1a53845157670378-2075HUMAN
PRESCRIPTION
DRUGLisinoprillisinoprilTABLETORAL20020701ANDAANDA076071Mylan
Pharmaceuticals Inc.LISINOPRIL20mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0378-2076_9195f48c-59af-471a-8522-1a53845157670378-2076HUMAN
PRESCRIPTION
DRUGLisinoprillisinoprilTABLETORAL20020701ANDAANDA076071Mylan
Pharmaceuticals Inc.LISINOPRIL40mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0378-2077_9195f48c-59af-471a-8522-1a53845157670378-2077HUMAN
PRESCRIPTION
DRUGLisinoprillisinoprilTABLETORAL20020701ANDAANDA076071Mylan
Pharmaceuticals Inc.LISINOPRIL30mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0378-3007_f0a7c860-39a5-433a-a3cb-44add1c485ec0378-3007HUMAN
PRESCRIPTION
DRUGCaptoprilcaptoprilTABLETORAL19960213ANDAANDA074434Mylan
Pharmaceuticals Inc.CAPTOPRIL12.5mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0378-3012_f0a7c860-39a5-433a-a3cb-44add1c485ec0378-3012HUMAN
PRESCRIPTION
DRUGCaptoprilcaptoprilTABLETORAL19960213ANDAANDA074434Mylan
Pharmaceuticals Inc.CAPTOPRIL25mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0378-3017_f0a7c860-39a5-433a-a3cb-44add1c485ec0378-3017HUMAN
PRESCRIPTION
DRUGCaptoprilcaptoprilTABLETORAL19960213ANDAANDA074434Mylan
Pharmaceuticals Inc.CAPTOPRIL50mg/1Angiotensin Converting Enzyme
Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors
[MoA]0378-3022_f0a7c860-39a5-433a-a3cb-44add1c485ec0378-3022HUMAN
PRESCRIPTION DRUGCaptopri